Post-approval studies (Phase 4)Study completedNCT03093480
What this trial is testing
Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Who this might be right for
Hemophilia A With Inhibitors
Bioverativ, a Sanofi company 16